AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform
Builds upon the neurodegenerative disease partnership announced in 2021
NORTH CHICAGO, Ill. and THOUSAND OAKS, Calif., Feb. 23... Biopharmaceuticals, Ophthalmology AbbVie, Capsida Biotherapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Adenoviruses | Brain | Genetics | Neurology | Opthalmology | Partnerships | Pharmaceuticals